Neuromuscular Disorders
Volume 17, Issue 6 , Pages 494-498 , June 2007

144th ENMC International Workshop: Outcome Measures in McArdle Disease, 29 September–1 November 2006, Naarden, The Netherlands

  • R. Quinlivan

      Affiliations

    • The Centre for Inherited Neuromuscular Disease, Robert Jones and Agnes Hunt NHS Trust, Gobowen, Oswestry, UK
    • Corresponding Author InformationCorresponding author.
    • ,
  • J. Vissing

      Affiliations

    • Neuromuscular Research Unit, Department of Neurology, and the Copenhagen Muscle Research Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

References 

  1. Mommaerts WFH, Illingworth B, Pearson CM, Guilorg RJ, Seraydarian K. A functional disorder of muscle associated with the absence of phosphorylase. PNAS. 1959;3:18–22
  2. Schmidt R, Mahler R. Chronic progressive myopathy with myoglobinuria: demonstration of a glycogenolytic defect in muscle. J Clin Invest. 1959;108:2044–2058
  3. Haller RG, Vissing J. Spontaneous “second wind” and glucose-induced second “second wind” in McArdle disease – oxidative mechanisms. Arch Neurol. 2002;59:1395–1402
  4. Andersen ST, Dunø M, Schwartz M, Vissing J. Do carriers of PYGM mutations have symptoms of McArdle disease?. Neurology. 2006;67:716–718
  5. Bartram C, Edwards RH, Clague J, Beynon RJ. McArdle’s disease a nonsense mutation in exon 1 of the muscle glycogen phosphorylase gene explains some but not all cases. Hum Mol Genet. 1993;2:1291–1293
  6. Beynon RJ, Quinlivan RCM, Sewry CA. Selected disorders of carbohydrate metabolism. In:  Karpati G editors. Structural and molecular basis of skeletal muscle disease. Wiley; 2002;p. 182–188
  7. Haller RG. Treatment of McArdle disease. Arch Neurol. 2002;57:923–924
  8. Bruno C, Cassandrini D, Martinuzzi A, et al. McArdle disease: the mutation spectrum of PYGM in a large Italian cohort. Hum Mutat. 2006;27:718–727
  9. Martinuzzi A, Sartori E, Fanin M, et al. Phenotype modulators in phosphorylase deficiency. Ann Neurol. 1993;53:497–502
  10. DiMauro S, Haller RG. Metabolic myopathies: substrate utilisation defects. In:  Griggs RC,  Schapira AV editor. Muscle diseases. Boston: Butterworth; 1999;p. 225–249
  11. Engel WK, Eyerman EL, Williams HE. Late-onset type of skeletal muscle phosphorylase activity. A new familial variety with completely and partial affected subjects. N Eng J Med. 1963;268:135–137
  12. DiMauro S, Hartlage P. Fatal infantile form of muscle phosphorylase deficiency. Neurology. 1978;28:1124–1129
  13. Cornelio F, Bresolin N, DiMauro S, et al. Congenital myopathy due to phosphorylase deficiency. Neurology. 1983;33:1383–1385
  14. Quinlivan RM, Beynon RJ. Pharmacological and nutritional treatment of McArdle’s disease (Glycogen storage disease V). Cochrane Database Syst Rev. 2004;3:CD003458
  15. Haller RG, Dempsey WB, Feit H, Cook JD, Knochel JP. Low levels of muscle pyridoxine in McArdle’s Syndrome. Am J Med. 1983;74:217–220
  16. Phoenix J, Hopkins P, Bartram C, Beynon RJ, Quinlivan R, Edwards RH. Effect of vitamin B6 supplementation in McArdle’s disease: a strategic case study. Neuromuscul Disord. 1998;8:210–212
  17. Vissing J, Haller RG. Effect of oral sucrose on exercise intolerance in patients with McArdle’s disease. N Eng J Med. 2003;349:2503–2509
  18. Vandenberghe K, Goris M, Van Hecke P, Van Leemputte M, Vangerven L, Hespel P. Long term creatine intake is beneficial to muscle performance during resistive training. J Appl Physiol. 1997;83:2055–2063
  19. Vorgerd M, Grehl T, Jager M, et al. Creatine therapy in myophosphorylase activity (McArdle’s disease). A placebo controlled crossover trial. Arch Neurol. 2000;57:956–963
  20. Vorgerd M, Zange J, Kley R, et al. Effect of high dose creatine therapy on symptoms of exercise intolerance in McArdle’s disease: double-blind placebo controlled cross-over study. Arch Neurol. 2002;59:97–101
  21. Schroers A, Kley R, Stachon A, et al. Gentamicin treatment in McArdle disease: failure to correct myophosphorylase deficiency. Neurology. 2006;66:285–286
  22. Busch V, Gempel K, Hack A, et al. Treatment of glycogenosis type V with ketogenic diet. Ann Neurol. 2005;58:341
  23. Haller RG, Wyrick P, Taivassalo P, Vissing J. Aerobic conditioning: an effective therapy in McArdle’s disease. Ann Neurol. 2006;59:922–928
  24. Ollivier K, Hogrel J-Y, Gomez-Merino D, et al. Exercise tolerance and daily life in McArdle’s disease. Muscle Nerve. 2005;31:637–641

PII: S0960-8966(07)00082-X

doi: 10.1016/j.nmd.2007.03.001

Neuromuscular Disorders
Volume 17, Issue 6 , Pages 494-498 , June 2007

Article Tools